MA26647A1 - Formulations de ziprasidone - Google Patents

Formulations de ziprasidone

Info

Publication number
MA26647A1
MA26647A1 MA25621A MA25621A MA26647A1 MA 26647 A1 MA26647 A1 MA 26647A1 MA 25621 A MA25621 A MA 25621A MA 25621 A MA25621 A MA 25621A MA 26647 A1 MA26647 A1 MA 26647A1
Authority
MA
Morocco
Prior art keywords
ziprasidone
formulations
ziprasidone formulations
Prior art date
Application number
MA25621A
Other languages
English (en)
Inventor
Robert Busch Frank
Ray Arenson Daniel
Rasadi Bijan
Carol Gatlin Hausberger Angela
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26647A1 publication Critical patent/MA26647A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
MA25621A 1998-06-15 1999-06-14 Formulations de ziprasidone MA26647A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
MA26647A1 true MA26647A1 (fr) 2004-12-20

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25621A MA26647A1 (fr) 1998-06-15 1999-06-14 Formulations de ziprasidone

Country Status (45)

Country Link
US (1) US6150366A (fr)
EP (1) EP0965343B1 (fr)
JP (2) JP3441676B2 (fr)
KR (1) KR100338915B1 (fr)
CN (1) CN1307994C (fr)
AP (1) AP1216A (fr)
AR (1) AR015553A1 (fr)
AT (1) ATE240732T1 (fr)
AU (1) AU753820B2 (fr)
BG (1) BG64691B1 (fr)
BR (1) BR9902268A (fr)
CA (1) CA2274338C (fr)
CO (1) CO5070579A1 (fr)
CY (1) CY2003002I1 (fr)
CZ (1) CZ297954B6 (fr)
DE (1) DE69908021T2 (fr)
DK (1) DK0965343T3 (fr)
EA (1) EA002223B1 (fr)
ES (1) ES2197581T3 (fr)
GT (1) GT199900080A (fr)
HK (1) HK1024184A1 (fr)
HN (1) HN1999000089A (fr)
HR (1) HRP990193B1 (fr)
HU (1) HU226487B1 (fr)
ID (1) ID23546A (fr)
IL (1) IL130424A (fr)
IS (1) IS2182B (fr)
MA (1) MA26647A1 (fr)
MY (1) MY121397A (fr)
NO (1) NO316713B1 (fr)
NZ (1) NZ336271A (fr)
OA (1) OA11064A (fr)
PA (1) PA8475601A1 (fr)
PE (1) PE20000632A1 (fr)
PL (2) PL195209B1 (fr)
PT (1) PT965343E (fr)
RS (1) RS49611B (fr)
SG (1) SG77243A1 (fr)
SI (1) SI0965343T1 (fr)
SK (1) SK286245B6 (fr)
TR (1) TR199901379A2 (fr)
TW (1) TW590774B (fr)
UA (1) UA59383C2 (fr)
UY (1) UY25649A1 (fr)
ZA (1) ZA993938B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
RS50089B (sr) * 1999-05-27 2009-01-22 Pfizer Products Inc., Suspenzija ziprasidona
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2263658A1 (fr) 2000-10-30 2010-12-22 Euro-Celtique S.A. Formulations d'hydrocodone à liberation lente
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
EP2301537A1 (fr) * 2002-05-17 2011-03-30 Duke University Zonisamide pour le traitement de l'obésité
AU2003300814A1 (en) * 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
WO2004050655A1 (fr) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
AU2003245027A1 (en) * 2003-04-11 2004-11-01 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
CN1784221B (zh) * 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
CA2528100A1 (fr) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Formes polymorphes de ziprasidone chlorhydrate et procedes pour leur elaboration
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
EP1663166A2 (fr) * 2003-09-02 2006-06-07 Imran Ahmed Formes posologiques a liberation prolongee de ziprasidone
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1687300A4 (fr) * 2003-11-28 2007-08-01 Wockhardt Ltd Procede de preparation de ziprasidone monochlorhydrate hydrate
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
EP1734955A2 (fr) * 2004-01-13 2006-12-27 Duke University Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
EP1744750A2 (fr) * 2004-05-06 2007-01-24 Sandoz AG Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
CA2467538C (fr) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
EP1753400A4 (fr) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr Forme de dosage de ziprasidone
CA2471219A1 (fr) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
RU2007106036A (ru) 2004-08-31 2008-10-10 Пфайзер Продактс Инк. (Us) Антитело к cd40: препарат и способы
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
EP1863806A1 (fr) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Ziprasidone mesylate amorphe
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (fr) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Synthese de sels d'addition acide de ziprasidone et de produits intermediaires connexes au moyen de reactions solide-gaz
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
EP1858892A1 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Mesylate de ziprasidone anhydre et son procede de preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1874268A1 (fr) * 2005-04-13 2008-01-09 Pfizer Products Inc. Formulations de depot injectables et procedes destines a assurer une liberation prolongee de compositions de nanoparticules
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
AU2006250340C1 (en) 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
EP1954241B1 (fr) * 2005-11-28 2012-02-29 Orexigen Therapeutics, Inc. Formulation de zonisamide a liberation prolongee
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (fr) * 2006-08-02 2008-03-05 Krka Formes polymorphiques de sulfates de ziprasidone
EP1892243A1 (fr) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Formes polymorphes de sels de sulfate de ziprasidone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
WO2009032558A2 (fr) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Préparation de chlorhydrate de ziprasidone monohydraté
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
EP2445343B1 (fr) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Promédicaments de composés nh acides
EP2340834A1 (fr) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Solubilité améliorée de la ziprasidone
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
SI3017811T1 (sl) 2010-02-25 2019-04-30 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2875056C (fr) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methodes de traitement de la surcharge ponderale et de l'obesite
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236B1 (fr) * 1996-02-13 2003-11-19 Pfizer Inc. Prodrogues de 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0901786B1 (fr) * 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue

Also Published As

Publication number Publication date
HU9901960D0 (en) 1999-08-30
ZA993938B (en) 2000-12-14
AU3398399A (en) 1999-12-23
PT965343E (pt) 2003-08-29
AP1216A (en) 2003-10-19
KR100338915B1 (ko) 2002-05-30
ID23546A (id) 2000-05-04
JP2000007566A (ja) 2000-01-11
CA2274338C (fr) 2003-04-15
HUP9901960A2 (hu) 2000-08-28
IL130424A (en) 2003-10-31
NZ336271A (en) 2000-10-27
EP0965343B1 (fr) 2003-05-21
CO5070579A1 (es) 2001-08-28
CN1242987A (zh) 2000-02-02
EP0965343A2 (fr) 1999-12-22
SG77243A1 (en) 2000-12-19
NO316713B1 (no) 2004-04-13
JP2002003492A (ja) 2002-01-09
PL195606B1 (pl) 2007-10-31
EP0965343A3 (fr) 2000-02-23
ES2197581T3 (es) 2004-01-01
CZ212799A3 (cs) 2000-09-13
UA59383C2 (uk) 2003-09-15
HK1024184A1 (en) 2000-10-05
US6150366A (en) 2000-11-21
PL195209B1 (pl) 2007-08-31
DE69908021T2 (de) 2003-11-27
HUP9901960A3 (en) 2000-09-28
IS2182B (is) 2006-12-15
ATE240732T1 (de) 2003-06-15
BG103489A (en) 2000-07-31
SK76999A3 (en) 2000-12-11
PA8475601A1 (es) 2000-09-29
SK286245B6 (sk) 2008-06-06
CZ297954B6 (cs) 2007-05-09
AP9901579A0 (en) 1999-06-30
OA11064A (en) 2002-03-13
TR199901379A2 (xx) 2000-01-21
GT199900080A (es) 2000-11-29
PE20000632A1 (es) 2000-07-26
RS49611B (sr) 2007-06-04
SI0965343T1 (en) 2003-10-31
UY25649A1 (es) 2000-02-23
BG64691B1 (bg) 2005-12-30
NO992892L (no) 1999-12-16
EA199900467A3 (ru) 2000-04-24
YU27199A (sh) 2002-12-10
HRP990193B1 (en) 2003-08-31
CA2274338A1 (fr) 1999-12-15
TW590774B (en) 2004-06-11
JP3441676B2 (ja) 2003-09-02
AR015553A1 (es) 2001-05-02
AU753820B2 (en) 2002-10-31
MY121397A (en) 2006-01-28
EA002223B1 (ru) 2002-02-28
KR20000006143A (ko) 2000-01-25
EA199900467A2 (ru) 1999-12-29
HN1999000089A (es) 1999-11-03
NO992892D0 (no) 1999-06-14
PL333737A1 (en) 1999-12-20
IL130424A0 (en) 2000-06-01
DK0965343T3 (da) 2003-08-04
HU226487B1 (en) 2009-03-02
IS5079A (is) 1999-12-16
BR9902268A (pt) 2000-05-02
DE69908021D1 (de) 2003-06-26
JP4187423B2 (ja) 2008-11-26
CN1307994C (zh) 2007-04-04
CY2003002I1 (el) 2009-11-04
HRP990193A2 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
MA26647A1 (fr) Formulations de ziprasidone
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1096937E (pt) Formulacoes de ranolazina de libertacao prolongada
PT1130966E (pt) Formulacoes antiparasitarias
DE69919953D1 (de) Funktionelle zusammensetzungen
ID29635A (id) Formulasi mikrokapsul
MA24473A1 (fr) Formulations
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
DE69920073D1 (de) kinderschutzhöschen
PT1218009E (pt) Grandulos de quetiapina
IS6398A (is) Lyfjablöndur
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
PT1218096E (pt) Microcapsulas de libertacao variavel
ID27655A (id) Formulasi mikrokapsul
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
DK0969233T3 (da) Strömningsbegrænser
PT1235566E (pt) Formulacao injectavel de valnemulina
PT1140068E (pt) Formulacoes de doramectina
PT1190776E (pt) Pulverizador de liquidos
ATA208398A (de) Handstück
SE9800766D0 (sv) Formulation
SE9800170D0 (sv) Formulation